ADAM17 and neoplasm: It is shown that suppressing cleavage of HER2 by INCB7839 (an ADAM10/ADAM17 inhibitor) decreases soluble HER2 ECD formation and also membrane p95 levels and subsequently renders tumor cells' response to treatment with trastuzumab [43].